Breast Isolated FLT3 Positive AML Relapse Treated with Gilteritinib in Monotherapy: Long- Term Follow-Up and Review of the Literature

Giulia Arrigo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Chiara Frairia(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Stefano D’Ardìa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Irene Urbino(University of Turin), Marco Cerrano(Assistance Publique – Hôpitaux de Paris), Valentina Giai(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Roberto Freilone(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Medical Research Archives
January 1, 2025
10.18103/mra.v13i5.6559
Cited by 0

Related Papers

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
|New England Journal of Medicine|2020|432
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
|Blood|2019|209
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission
|Blood|2019|97
Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patients
|Annals of Oncology|1998|93
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome
|Transplantation and Cellular Therapy|2016|88